DISCOVERY CLINICAL DEVELOPMENT
EXPLORATORY LEAD OP IND-ENABLING PHASE 1 PHASE 2 PHASE 3

PRIVILEGED CHEMOTYPE LIBRARY

Bipolar Depression (Lead Program)
Treatment-Resistant Depression (TRD)
Schizophrenia (Exscientia)
Geriatric Psychosis (Exscientia)

Bipolar depression:
OAK-0011379

Existing drug classes are relatively ineffective for treating the 6 million adult Americans with bipolar disorder and maintenance. Our lead drug candidate, OAK-0011379, exhibits in vivo activity that will help predict efficacy as a rapid-acting and sustained antidepressant for people with bipolar disorder.

LEARN MORE

Geriatric Psychosis:
OAK-0011799

There have been no new mechanisms-of-action approved in the last 40 years for treating geriatric psychosis and schizophrenia, and existing drugs often produce severe side effects. OAK-0011799 optimizes dual targeted small molecules for a historic opportunity to develop superior classes of therapeutics for those suffering from these disorders.

LEARN MORE

News from Blue Oak

Nimh Award

Blue Oak awarded a $2.9M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.

Read

Press Release

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.

October 14, 2020 US startup Blue Oak Pharma has joined

Fund Raising

Viva Biotech Holdings leads Series A funding round, alongside ShangPharma Innovation and JMCR Family Partners, to advance the Blue Oak R&D pipeline in psychiatric drugs.

Publication

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions

Presentation

Blue Oak delivers a podium presentation at the Keystone Meeting on Phenotypic Drug Discovery describing a systems neurobiology approach to discovering the next generation of drugs for bipolar depression.

Nimh Award

Blue Oak awarded a $900,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.

NIMH Funding

Blue Oak has received sustained funding from the National Institute of Mental Health (NIMH) to support drug discovery and clinical development.

Key Partnerships

Shang Pharma innovation
Exscientia
Sprout BioVentures
IVA Biotech
JMCR Family Office
PDSP
Porsolt
PsychoGenics
SB Drug Discovery
EuMentis

Join Our Fight Against Brain Disorders

For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.

CONTACT US
caret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-square